Immunohistochemical Expression of Programmed Death Ligand 1(PDL1) in Endometrial Carcinoma and Its Relation to CD4 and CD8 Positive Immune Cells

Abstract

Objectives: Endometrial cancer (EC) is the most common cancer of the female genital tract. Egypt showed a significant increase in incidence lately of which 25% were premenopausal. Advanced or recurrent disease are mostly unresectable and the traditional adjuvant therapy give modest results with devastating side effects. Late discoveries of immune checkpoint inhibitors have produced promising results. Programmed cell death 1 (PD1) is an immune inhibiting receptor on surface of lymphocytes, which plays critical roles in maintaining immunological self-tolerance. There are two ligands for this receptor, PDL1 and PDL2. PD-L1 is expressed on tumor cells; attaches to PD1, allowing tumor cells to escape from the host immune response. Its prognostic significance in various tumors is controversial and its significance in ECs has just begun to be investigated. Therefore, we investigated the relationship between PDL1 expression and different clinicopathologic parameters in EC cases and its correlation with CD4 and CD8 immune cells, in order to identify the predictive biomarkers for the outcome by immune therapy. Methods: Hundred, paraffin tissue blocks of EC cases were collected and stained with antibodies against PDL1,CD4 and CD8. Results: PDL1 was positive in 67% of cases in tumor cells and in 61% of cases in immune cells. CD4 and CD8 were expressed in 79% of cases. Statistically significant correlations were observed between PDL1 expression and patients mean age, LVSI, TILS score and CD4+/CD8+ expression. Conclusion: Those variables can stratify candidates who can benefit most from immunotherapy, or can be chosen for further high cost molecular investigations application.

Evaluating CD4 and Foxp3 mRNA Expression in Tissue Specimens of Celiac Disease and Colorectal Cancer Patients

“…The CD4 +/CD8+ ratio was higher in low-grade specimens, suggesting that CD4 + and CD4 +/CD8+ ratio are independent prognostic factors in OSCC [ 32 ]. Salama et al [ 33 ] investigated the correlation between PDL1 expression and clinicopathological parameters in endometrial cancer (EC) cases, focusing on CD4 and CD8 immune cells. They found that PDL1 was expressed in tumor cells in 67% of cases and in immune cells in 61% of cases.…”

“…Significant correlations were observed between PDL1 expression and patient age, LVSI, TILS score, and CD4 +/CD8+ expression. The findings suggest that these variables may serve as predictive biomarkers for successful immune therapy in EC [ 33 ].…”

Association Between Gadoxetic Acid-Enhanced Magnetic Resonance Imaging, Organic Anion Transporters, and Farnesoid X Receptor in Benign Focal Liver Lesions

“…In human hepatocellular carcinoma (HCC) specimens, expression of FXR is markedly decreased in comparison with the level in normal liver (van den Esschert et al, 2011). A recent immunohistochemical analysis on 17 primary HCC cases and 21 non-neoplastic hepatic lesions (i.e., FNH, regenerative nodules, and dysplastic nodules) revealed that FXR expression level was lower in HCC than in non-neoplastic lesions (Salama et al, 2023). The expression and activation of FXR in HCA and its potential role in the malignant transformation of HCA into HCC has not yet been investigated.…”

The Inhibition Mechanism of Pancreatic Ductal Adenocarcinoma via LXR Receptors: A Multifaceted Approach Integrating Molecular Docking, Molecular Dynamics and Post-MD Inter-Molecular Contact Analysis

“…Liver's X receptors, and have inhibiting LXR activity has been observed to curb cell proliferation and enhance responsiveness to chemotherapy. (Salama et al, 2023;Srivastava et al, 2020).…”